Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.60 |
| ▸ | NQO2 | P16083 | 12/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175565 | 0.87 | TRPV1 (0.50) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL8886502 | 0.84 | MTNR1A (0.62) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL8887662 | 0.83 | MTNR1A (0.72) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL8885947 | 0.83 | MTNR1A (0.67) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL8887067 | 0.82 | MTNR1A (0.73) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL315536 | 0.79 | HTR6 (0.67) | — | |
| SCHEMBL315535 | 0.79 | HTR6 (0.67) | — | |
| SCHEMBL8886469 | 0.78 | MTNR1A (0.82) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5172930 | 0.78 | SIGMAR1 (0.61) | — | |
| SCHEMBL315842 | 0.77 | KDM4C (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | MTNR1A 31/4885MTNR1B 29/4885NQO2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.